Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

COVID-19 Study Assessing the Efficacy and Safety of Anti-Spike SARS CoV-2 Monoclonal Antibodies for Prevention of SARS CoV-2 Infection Asymptomatic in Healthy Adults and Adolescents Who Are Household Contacts to an Individual With a Positive SARS-CoV-2 RT-PCR Assay

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04452318
Recruitment Status : Active, not recruiting
First Posted : June 30, 2020
Last Update Posted : May 4, 2021
Sponsor:
Information provided by (Responsible Party):
Regeneron Pharmaceuticals

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : September 25, 2021
Estimated Study Completion Date : September 25, 2021
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):